Best of ASCO China breast cancer articles

Schematic diagram of breast cancer

· Current on T1 ~ 2N0 ~ 1 issues (< 5 cm tumor, lymph node number is 1 ~ 3) breast cancer patients treated with radical mastectomy for radiotherapy is still disputed;

· Bevacizumab combined with Capecitabine, anthracyclines/taxol class chemotherapy first-line treatment of metastatic breast cancer, may improve survival without progress (PFS);

· Polymeric adenosine diphosphate ribose polymerase (PARP) inhibitor refractory breast cancer shows a certain effect, subject to the third stage of clinical studies.

Early breast cancer

For 2009, the United States society of Clinical Oncology (ASCO) annual meeting in early breast cancer study collection, the Academy of military medical sciences affiliated hospital (PLA 307 hospital) jiangze flew Professor organizations discussed scholars.

For Professor Jiang's how to treat this year, ASCO's annual meeting for T1 ~ 2N0 ~ 1 period of research findings in patients with breast cancer, the Chinese Academy of Medical Sciences Professor Yu zihao's Cancer Hospital, currently on T1 ~ 2N0 ~ 1 mastectomy patients with breast cancer and adjuvant chemotherapy is given after the controversial radiotherapy. As noted by the researchers, the research methodology exists two obvious defects, first of all, this is a retrospective study, followed two groups of patients in treatment is not completely consistent, will receive mastectomy patients and patients with breast-conserving therapy accepted for comparison is not always appropriate, therefore we have carefully results for this study. Some of the ongoing research may be able to give answers to this problem.

Guangdong provincial people's Hospital, the Guangdong provincial Lung Cancer Institute Professor Wu a dragon of radiotherapy for breast cancer patients with long-term effects, Professor Yu zihao's introduction, radiotherapy long-term follow-up has been more concerned about the problem. Before you consider breast cancer radiation therapy is the major complications of cardiac toxicity, but now with the irradiation technology standards, long-term follow-up results of radiation therapy for cardiac toxicity did not increase significantly, so if you can strictly control the indications and guarantee the quality of radiation technology, radiation therapy should not be cause long-term effects in patients with breast cancer.

Advanced breast cancer and breast cancer drug

For advanced breast cancer and breast cancer research, new selection of United States Washington Cancer Institute Swain (Swain) are summarized.

Advanced breast cancer treatment is mainly based on the biology of cancer, estrogen receptor (ER) and/or progesterone receptor (PR) positive people may choose hormone therapy; for ER and (or) PR-negative or endocrine treatment of tolerance, if human epidermal growth factor receptor 2 (HER2) overexpression, chemotherapy and Trastuzumab treatment of HER2 expression, if negative, you can choose to chemotherapy.

Although the combined with chemotherapy in remission rate and overall survival (OS) has certain advantages, but greater toxicity. Therefore, unless it is in urgent need to reduce tumor load conditions, generally it is recommended to select a single-drug therapy. But clinical or should be based on the biology of cancer, treatment, patients will, tumor load, and so on comprehensive measure to determine the choice of treatment. AVADO study E2100 and have confirmed that bevacizumab combined with taxane first-line therapy in MBC improves PFS, ASCO Annual meeting this year RIBBON-1 studies show that bevacizumab combined with anthracyclines, Capecitabine chemotherapy also may extend PFS period, but no significant differences in the OS.

PARP inhibitor selectivity killer BRCA1/2 gene defect cell. In addition, the gene expression profile displays, in a majority of three-negative breast cancer (ER, PR and HER2 are negative, TNBC) significant increases in PARP1 patients. This year, ASCO's annual meeting of the two phase II study results confirmed that the PARP inhibitor BSI-201 and olaparib for three negative breast cancer and BRCA mutations in breast cancer encouraging, but the second stage of the results is not sufficient to conclude that the best treatment option for precise conclusions, should be treated with caution.

(Liao Lily)

Some featured research

· A study shows that the United States, for example T1 «4240 2N0 ~ 1-stage breast cancer, mastectomy no postoperative radiation therapy to the distant metastasis risk significantly higher than the portion after postoperative radiation therapy (HR = 1.38, P = 0.002).

(Report Yu zihao 's)

· RIBBON-1 research shows that for 1237 cases have not previously received treatment for metastatic breast cancer patients, Capecitabine or taxanes/anthracycline joint bevacizumab can significantly extend PFS period (the researchers assessed 8.6 months pair 5.7 months; 9.2 months pair 8.0 months), but the OS was not significantly improved.

(The speaker jiangze fly)

· A phase II study of Gemcitabine + carboplatin chemotherapy in BSI-201 can significantly extend the OS issue (9.2 months pair 5.7 months); another study shows at stage, olaparib (400 mg, twice daily oral) treatment of BRCA mutations in patients with advanced breast cancer in remission rate of 41%, PFS 5.7 months period.

(Fudan University Cancer Hospital reported person Hu XI Chun)

(Editors: Deng 1m1m Yihong)

How can I get a membership card number?

A: to access this site membership card number, you first need to become a member of this website. This site is divided into registered members and members of their members. Registered members have the Member's account number and card member owned is the membership card number.

Obtaining membership card number of the owner of the company's products, including a registration card, health card, female, Golden and cooperation with our company's various cooperation issued the card.

Cooperation is jointly developed with cooperation unit, this card uses an object generally established for cooperation between units. So the card is not foreign sales.

So you can only buy our product cards, become our valued members, we have a your own membership card number.

Purchase card as follows:

First, in cooperation with the hospital site purchase, place of purchase as follows:

The first affiliated hospital of Guangzhou University

Guangdong provincial hospital

Guangzhou subsidiary orthopedics hospital

Guangdong provincial hospital II sand branch

Guangdong provincial hospital fangcun branch (charity hospital)

The first affiliated hospital of Sun Yat-sen University

Sun Yat-sen University affiliated hospital

The third affiliated hospital of Sun Yat-sen University

First people's Hospital, Guangzhou, China

The second people's Hospital, Guangzhou, China

Armed Police Corps Hospital in Guangdong

The first affiliated hospital of Guangzhou University second clinic

Guangzhou overseas Chinese hospital

Southern Medical University South hospital

Guangzhou Guangzhou General Hospital

Guangzhouyixueyuandi Hospital (workers ' hospital)

The second affiliated hospital

Guangzhou haizhu district hospital

Guangdong Provincial Dental Hospital

Guangzhou Red Cross Hospital

Guangzhou City Hospital

Foshan City Hospital

Guangzhou design concept (hospital)

Dongguan's Hospital-flexible Dhi clinic

Second, the purchase by mail, as follows:

Account number: 3602 0009 1920 0108 663

Guangzhou University Network co., Ltd.

Bank：ICBC Beijing Road branch

Notes:

Please fill out the customer according to the above, the cash payment orders will be bank receipt by fax to 020-34255801

Fax orders please include your full address so that we can send you your membership card.

Please pay in cash for a single purpose: to write out column Tel, buys the card fee/renew fee, renew please indicate the old card number: * ** * ** * **.

Coins don't amount to RMB remittance = buys the card/renew fee + courier fee of $ 18.

Temporarily not accepting foreign, remittance, please consult: 020-34255692.

3. directly to the company headquarters to purchase:

Company address: haizhu district of Guangzhou Pearl River Riverside road No. 813 square, third floor network company

Online buys the card as described in this website product monopoly column of the page.

(Editors: Dawn 1m1m)

How to become a Member?

Become a member there are two ways, one is to become a site member, also known as a registered member, the other is a member of the preregistration. To become a registered member of this site, you just need to click on the top of the Home site, as well as other pages are "registered", follow the prompts to register successfully. To become a member of preregistration, simply our major cooperative hospital fill out the free application for preregistration, staff within five working days to fill in the information and be audited. Their customers, I use only the applicant, a doctor is required to carry a valid document, sequence ID, medical card access number, the real-name system not only avoid fried, behavior, and more to protect the vital interests of the applicant.

(Editors: Dawn 1m1m)